| Day 1 – Selected Poster Presentations (1 October 2026, 15:30–16:15, Poster Area) |
| Poster No |
Abstract Title |
Speaker |
| Chairs: Christina Duftner, Abdurrahman Tufan |
| PP-1 |
The ultrasound tool “superb microvascular imaging” (SMI) strengthens a diagnosis of GCA relapse |
Christina Svensson |
| PP-4 |
Automated vessel wall thickness measurement, the future in vasculitis ultrasound? A vessel phantom study |
Fedde Broekman |
| PP-8 |
Musculoskeletal ultrasound for monitoring polymyalgia rheumatica – changes during remission and induced relapse |
Christoffer Soevsoe Vaaben |
| Chairs: Carlo Salvarani, Cemal Bes |
| PP-2 |
Correlation of pulse loss or limb claudication with arterial lesions in Takayasu’s Arteritis |
Tanaz A Kermani |
| PP-3 |
Aortic imaging surveillance in Giant Cell Arteritis (GCA): A retrospective service evaluation of current practice and outcomes |
Samiksha Kumar |
| PP-5 |
First experience of ultra-high resolution NeuroEXPLORER FDG PET/CT in patients with Giant Cell Arteritis |
Lennert Boeckxstaens |
| Chairs: Amr Sawalha, Gökçe Kenar Artın |
| PP-6 |
Deep Learning based Multi-Feature Fusion Model for Predicting Neurological Severe Ischemic Events in Supra-Aortic Takayasu Arteritis |
Sun Ying |
| PP-7 |
Genome-wide comparison of genetic susceptibility to Polymyalgia Rheumatica and Giant Cell Arteritis reveals distinct genetic architectures |
Dimitra Ilektra Lerou |
| PP-11 |
Mortality in patients with polymyalgia rheumatica: a Danish nationwide cohort study |
Johanne Cecilie Krogh Madsen |
| Chairs: Milena Bond, Ayşe Çefle |
| PP-9 |
Prospective follow-up of 4 years in Takayasu Arteritis: Results of Turkish Takayasu Arteritis Inception Cohort |
Fatma Alibaz Oner |
| PP-10 |
Compression Ratio and Intima–Media Thickness Quantify Distinct Aspects of the Ultrasonographic Halo in Giant Cell Arteritis |
Muhammad Asim Khurshid |
| PP-12 |
Demographic and cardiovascular determinants of intima–media thickness in non‑GCA patients: implications for segment‑specific ultrasound thresholds |
Muhammad Asim Khurshid |
|
|
|
| **Day 2 – Selected Poster Presentations (2 October 2026, 15:00–15:45, Poster Area)** |
| Poster No |
Abstract Title |
Speaker |
| Chairs: Sara Monti, Burak Ince |
| PP-13 |
Secukinumab in patients with polymyalgia rheumatica: 52-week primary and subgroup results from a Phase 3, multicentre, randomised, double-blind, placebo-controlled trial (REPLENISH) |
Christian Dejaco |
| PP-14 |
Response to Upadacitinib in New-Onset Versus Relapsing Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial |
Christian Dejaco |
| PP-16 |
The Impact of Aneurysm Presence on the Course of Takayasu Arteritis: A Retrospective Tertiary Center Experience |
Aysegul Avcu |
| Chairs: Alessandro Tomelleri, Sema Kaymaz Tahra |
| PP-15 |
Early use of sarilumab in patients with glucocorticoid-resistant polymyalgia rheumatica improves outcomes – insights from randomized controlled trial and real-world data |
Wolfgang Schmidt |
| PP-17 |
Long-Term Comparison of Tofacitinib and Tocilizumab in Refractory Takayasu’s Arteritis |
Jing Li |
| PP-18 |
Impact of Aspirin and Statin Use on Prognosis in Takayasu Arteritis |
Fatih Yıldırım |
| Chairs: Takahigo Sugihara, Şule Yaşar Bilge |
| PP-19 |
Risk of Dementia in Patients with Giant Cell Arteritis Treated with Steroid monotherapy vs. Steroid-Sparing Therapy: A Single Center Retrospective Study |
Ahmad Alkhatib |
| PP-20 |
Retinal Findings in Takayasu Arteritis: 10-Year Follow-Up Results |
Fehim Esen |
| PP-21 |
A Comprehensive Prognostic Architecture for Takayasu Arteritis: From Data-Driven Phenotypes to an Individualized Risk Prediction Tool |
Gokce Kenar Artin |
| Chairs: Kornelis Van Der Geest, Gezmiş Kimyon |
| PP-22 |
Evaluation of the Novel Composite Scores PIMS-1 and PIMS-2 in the Diagnosis, Disease Activity Monitoring and Prognostication of Polymyalgia Rheumatica |
Patricia Harkins |
| PP-23 |
Characterising the Inflammatory Architecture of Polymyalgia Rheumatica Using Multiplex Biomarkers and Systems Level Analyses |
Patricia Harkins |
| PP-24 |
Visual Manifestations in Giant Cell Arteritis Represent a Distinct Clinical Phenotype Despite Similar Ultrasound Disease Burden |
Danielle Molloy |
